Yes. The link between estrogen and dermal collagen is one of the most decisively established relationships in skin biology, with foundational data going back forty years and continuous confirmation since.
Estradiol — the primary estrogen — acts directly on dermal fibroblasts through estrogen receptor alpha and beta pathways. Activation of those receptors upregulates the genes that produce type I and type III collagen, the two most abundant collagens in skin. When estradiol is high, fibroblasts produce more collagen. When estradiol falls, they produce less. The mechanism is direct and dose-dependent.
The clinical consequences are measurable. Brincat and colleagues at King's College Hospital established the foundational data in 1983, showing that skin collagen content in postmenopausal women declines linearly with time since menopause (Brincat, 1983). The steepest loss occurs in the first five years — approximately 30% of dermal collagen — with slower ongoing loss thereafter (Affinito, 1999).
Verdier-Sévrain synthesized the mechanistic evidence comprehensively in a widely-cited 2006 review, detailing the specific pathways through which estradiol supports fibroblast function, skin thickness, wound healing, and matrix protein synthesis (Verdier-Sévrain, 2006).
What this means practically: perimenopausal and postmenopausal women can expect measurable skin thinning and elasticity loss driven directly by hormonal decline. Menopausal hormone therapy (HRT/MHT) has evidence for slowing or partially reversing this in appropriately-selected women (NAMS, 2022).
Estradiol is one of the nine biomarkers on the JenSkin panel because measuring where your estrogen is right now gives you an actionable baseline.